Simvastatin Reduces Circulating Plasminogen Activator Inhibitor 1 Activity in Volunteers with the Metabolic Syndrome

BACKGROUND: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)–cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang, Long, Rockwood, Jason, Zak, Danielle, Devaraj, Sridevi, Jialal, Ishwarlal
Formato: Artigo
Lenguaje:Inglês
Publicado: Mary Ann Liebert, Inc. 2008
Materias:
Original Papers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2692921/
https://ncbi.nlm.nih.gov/pubmed/18484901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/met.2008.0012
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares